Filing Details
- Accession Number:
- 0001415889-23-011951
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-08 21:05:17
- Reporting Period:
- 2023-08-07
- Accepted Time:
- 2023-08-08 21:05:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1267813 | Marinus Pharmaceuticals Inc. | MRNS | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1643875 | Scott Braunstein | 5 Radnor Corporate Center, Suite 500 100 Matsonford Rd Radnor PA 19087 | Chairman And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-08-07 | 6,413 | $9.55 | 160,792 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-08-08 | 30 | $8.94 | 160,762 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.
- The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.18 to $10.15, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Billionaire Hedge Funds
